Funding or Fundraising-Announcements

WaveCheck raises over $41,000 for breast cancer treatment monitoring in three weeks

Over 340 people worldwide have joined WaveCheck‘s Indiegogo crowdfunding campaign to fund a breakthrough clinical technique for breast cancer that promises to revolutionize the way chemotherapy is monitored.

“Breast Cancer Awareness Month’s positivity makes it easy to overlook the fact that 60 to 70 per cent of chemotherapy treatments fail,” says Dr. Gregory Czarnota, chief of Radiation Oncology at Sunnybrook Health Sciences Centre and co-inventor of WaveCheck with Professor Michael C. Kolios of Ryerson University. “WaveCheck’s technology can tell people with breast cancer and their doctors if a particular chemotherapy is working in as little as four weeks.”

WaveCheck’s campaign made the Top 10 list for the most financially successful Canadian crowdfunding campaigns on both Kickstarter and Indiegogo in Globe and Mail’s Report on Small Business. CTV News Channel, CBC Toronto News (see the above clip), CBC Radio Canada and Canadian Healthcare Technology have also covered the project, along with Oshawa Today (radio), The Ryersonian and The Eyeopener.

ChipCare’s handheld analyzer attracts one of Canada’s largest-ever healthcare angel investments

September 16, 2013
Susanne Staer
ChipCare Corporation

Device could significantly improve HIV diagnostics in developing world

OTTAWA, September 16, 2013 — An innovative, handheld point-of-care analyzer, developed by ChipCare Corporation, has secured one of the largest ever angel investments in Canada’s healthcare sector.

Phase II financing has closed, with an investment of $2.05M to support ChipCare’s continuing development and commercialization over the next three years.

Media coverage: Biotechnology Focus, TechVibes, BetaKit, Healthrender, Crunchbase, Toronto Star and VentureLab.

The financing evolved through a uniquely collaborative funding model among Canadian social angel investors, including Maple Leaf Angels, MaRS Innovation and the University of Toronto (Connaught Fund), with special financing leadership from Grand Challenges Canada and the Government of Canada.

Cellax profiled in SciBX; MaRS Innovation’s MSc PoP program cited in National Post supplement

The Cellax technology was profiled in a recent issue of SciBX (subscription necessary). MaRS Innovation is mentioned in the article as the technology’s commercialization agent.

Here’s an excerpt:

“Ontario Institute for Cancer Research scientists have developed glycopolymer-conjugated docetaxel nanoparticles that outperform Abraxane in mouse models of breast cancer. The Ontario Institute for Cancer Research (OICR) is backing the program with $1.5 million to take it to the clinic. The expectation is that the product’s ability to target the tumor stroma rather than the tumor itself will differentiate it from Abraxane and other chemotherapeutic formulations.”

Call for Applications: MaRS Innovation seeks applicants for early-stage MSc POP projects

September 4, 2013
Susanne Staer
BresoTec Inc.

MaRS Innovation (MI) seeks applicants for the Medical Sciences Proof-of-Principle (MSc PoP) program, which supports early-stage medical science technologies and allows their founding teams to conduct crucial proof-of-principle work.

Through the two-year MSc POP program, MI will distribute funding awards to qualified applicants within its membership on behalf of the Ministry of Research and Innovation (MRI). Funds are available in $25,000 or $75,000 grants.

“At MaRS Innovation, the PoP program functions as a kind of internal Dragons’ Den,” says Dr. Raphael Hofstein, president and CEO of MaRS Innovation. “For three years, we’ve used a panel of industry leaders to hear pitches from the founding teams of the most promising technologies in our intellectual property pipeline. Based on their assessments, the strongest projects receive PoP funding to fuel their prototyping and other proof-of-principle work.”

Yonge Street Media: Crowdmark, moderated marking and helping teachers grade better

June 19, 2013
Susanne Staer
Crowdmark

Yonge Street Media, a weekly online magazine that covers talent, innovation, diversity and quality of life stories in the Toronto region, covered Crowdmark‘s efforts to disrupt the way teachers grade and interact with students in their Innovation section on Wednesday, June 19, 2013.

Crowdmark graduated from the UTEST program earlier this spring. Last week, the company announced it has raised $600,000 in seed funding and completed two successful proof-of-concept pilot projects. Its co-founders are from the University of Toronto.

Here’s an excerpt from Hamutal Dotan‘s article (emphasis ours):

It is the bane of every teacher’s existence: grading. Though essential, it’s also repetitive and time-consuming. It is also increasingly prone to concerns about inequity: from grade inflation to inconsistent standards across different classrooms, sometimes parents, students, and even teachers themselves have a hard time deciding just what the grades they have assigned actually mean.

Aiming to help with both those problems is Toronto startup Crowdmark. Founded by two University of Toronto mathematics experts–the department’s associate chair, James Colliander, and graduate student Martin Muñoz–Crowdmark provides teachers with a suite of tools to facilitate faster grading, and enables teachers to handle large volumes of grading collaboratively.

Crowdmark to save teacher marking time and government dollars

June 11, 2013
Susanne Staer
Crowdmark

Ed-tech start-up completes successful EQAO and Canadian Open Math Challenge pilots

TORONTO, Canada (June 11, 2013) — Crowdmark Inc., a Canadian education technology start-up, is positioned to save cash-strapped Departments of Education millions by making massive-scale testing more efficient. Crowdmark has raised $600,000 in seed funding through the University of Toronto Early-Stage Technology (UTEST) program, MaRS Innovation and U of T’s Connaught Fund, among others.

This story was covered by Yonge Street Media, TechVibes, EdSurge and PEHub.

Dr. James Colliander, co-founder and CEO of Crowdmark — **Dr. James Colliander**, co-founder and CEO of Crowdmark.

The Crowdmark assessment interface, informed by decades of teaching experience and research by company co-founders, James Colliander (Professor of Mathematics) and Martin Muñoz (Researcher and Developer), at the University of Toronto, streamlines the complicated and time-consuming grading workflow for teachers.

Crowdmark archives student work and all grading feedback into individual digital portfolios that students and parents may access any time online and via mobile devices.

Through two separate pilot projects, Crowdmark has achieved proof-of-concept as a novel and scalable solution to the problem of assessment blockage that eats into already limited resources in education systems worldwide.

MaRS Discovery District launches MaRS EXCITE to help breakthrough technologies reach patients faster

MI start-up ApneaDx Inc. among program’s first round of participants

The first three companies selected to participate in the MaRS EXCITE program aim to improve outcomes for breast cancer, sleep apnea and drug-resistant hypertension.

The Excellence in Clinical Innovation and Technology Evaluation (EXCITE) initiative helps companies accelerate the adoption and reimbursement of innovative health technologies through a single, harmonized, pre-market, evidence-based process.

EXCITE has selected ApneaDx Inc., Medtronic of Canada Ltd. and Rna Diagnostics Inc. as the program’s initial participants.

MaRS Innovation announces new strategic partnership with Pfizer

TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics.

Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.

“There’s growing consensus that transferring technologies from the university lab bench and into the market requires unique public-private partnerships,” said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. “Partnering with MaRS Innovation gives Pfizer access to Toronto’s robust innovation pipeline and a close look at emerging IP from Canada. It signals both the strength and attractiveness of our commercialization model and Toronto-based research technologies to global industry players.”

“Our government is committed to making Ontario the best place to translate great ideas into innovative products that will gain demand around the world,” said the Honourable Reza Moridi, Ontario Minister of Research and Innovation. “Today’s announcement from MaRS Innovation is an exciting collaboration with Pfizer that will both advance healthcare technologies for Ontarians and help to strengthen our economy.”

Merck invests in pan-Canadian life sciences research innovation sector

A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada

CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector.

Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for Commercialization and Research (CECRs) based in Ontario and in British Columbia.

This partnership announcement was covered by PEHub.

IRICoR will work in conjunction with MaRS Innovation and the Centre for Drug Research and Development (CDRD) to identify, develop and commercialize technologies in healthcare. All three CECR institutions – identified as CECR in 2008 by the federal government – share a common objective: facilitating and accelerating the commercialization of research breakthroughs that will improve the quality of life of Canadians and others around the world.

Minuum’s crowdfunding campaign raises 873 per cent of initial goal

Over 9,600 people funded Toronto start-up’s one-dimensional mobile keyboard

Final tally for Minuum's Indiegogo campaign — The final tally for Minuum’s Indiegogo campaign: $87,369 in one month from 9,648 supporters.

TORONTO, Canada (April 18, 2013) — The Indiegogo campaign for Minuum, “the little keyboard for big fingers,” created by Whirlscape Inc., has closed after raising $87,369 in one month.

Minuum is a one-dimensional, tiny keyboard that frees up mobile screen space while allowing fast, accurate typing. Its specialized, patent-protected auto-correction algorithm allows highly imprecise typing, configuring the difference between what you type and what you mean in real time and getting it right even if you miss every single letter.

Read about the Minuum launch and reaching its $60,000 stretch milestone in previous posts. The posts include links to Minuum’s international media coverage. Most recently, their technology and Indiegogo success were featured in The Verge, the Financial Post, Mobile Syrup (includes an excellent Youtube interview with founder Will Walmsley, embedded below) and Tech2.

The campaign’s initial goal — $10,000 to fund the launch of an Android keyboard app — was reached within 14 hours. Since its launch on March 18, the campaign video has been viewed over 1.1 million times.

Did you know Minuum’s campaign is in Indiegogo’s top 10 of all time for projects with the largest number of supporters?